Scopus BioPharma (SCPS) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrends SCPS vs. NAVB, VAXX, AMPE, EVLO, CMRA, GNCA, STAB, CALA, CLVR, and EFTRShould you be buying Scopus BioPharma stock or one of its competitors? The main competitors of Scopus BioPharma include Navidea Biopharmaceuticals (NAVB), Vaxxinity (VAXX), Ampio Pharmaceuticals (AMPE), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Genocea Biosciences (GNCA), Statera Biopharma (STAB), Calithera Biosciences (CALA), Clever Leaves (CLVR), and eFFECTOR Therapeutics (EFTR). These companies are all part of the "pharmaceutical products" industry. Scopus BioPharma vs. Navidea Biopharmaceuticals Vaxxinity Ampio Pharmaceuticals Evelo Biosciences Comera Life Sciences Genocea Biosciences Statera Biopharma Calithera Biosciences Clever Leaves eFFECTOR Therapeutics Scopus BioPharma (NASDAQ:SCPS) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends. Do insiders and institutionals believe in SCPS or NAVB? 0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. 5.1% of Scopus BioPharma shares are owned by company insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media prefer SCPS or NAVB? In the previous week, Navidea Biopharmaceuticals had 1 more articles in the media than Scopus BioPharma. MarketBeat recorded 1 mentions for Navidea Biopharmaceuticals and 0 mentions for Scopus BioPharma. Scopus BioPharma's average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score. Company Overall Sentiment Scopus BioPharma Neutral Navidea Biopharmaceuticals Neutral Does the MarketBeat Community prefer SCPS or NAVB? Scopus BioPharma received 2 more outperform votes than Navidea Biopharmaceuticals when rated by MarketBeat users. Likewise, 100.00% of users gave Scopus BioPharma an outperform vote while only 0.00% of users gave Navidea Biopharmaceuticals an outperform vote. CompanyUnderperformOutperformScopus BioPharmaOutperform Votes2100.00% Underperform VotesNo VotesNavidea BiopharmaceuticalsOutperform VotesNo VotesUnderperform Votes76100.00% Which has more risk and volatility, SCPS or NAVB? Scopus BioPharma has a beta of -0.19, meaning that its stock price is 119% less volatile than the S&P 500. Comparatively, Navidea Biopharmaceuticals has a beta of 1.94, meaning that its stock price is 94% more volatile than the S&P 500. Which has preferable valuation and earnings, SCPS or NAVB? Scopus BioPharma has higher earnings, but lower revenue than Navidea Biopharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioScopus BioPharmaN/AN/A-$11.61MN/AN/ANavidea Biopharmaceuticals$70K1.14-$15.18MN/AN/A Is SCPS or NAVB more profitable? Company Net Margins Return on Equity Return on Assets Scopus BioPharmaN/A N/A N/A Navidea Biopharmaceuticals N/A N/A N/A SummaryNavidea Biopharmaceuticals beats Scopus BioPharma on 5 of the 8 factors compared between the two stocks. Get Scopus BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for SCPS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SCPS vs. The Competition Export to ExcelMetricScopus BioPharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$10,000.00$7.05B$5.84B$9.15BDividend YieldN/A2.75%4.75%3.85%P/E RatioN/A5.9726.4719.17Price / SalesN/A268.05435.3370.72Price / CashN/A65.6738.0134.83Price / BookN/A6.707.644.62Net Income-$11.61M$138.76M$3.19B$246.06M Scopus BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SCPSScopus BioPharmaN/AN/AN/A-91.7%$10,000.00N/A0.009NAVBNavidea BiopharmaceuticalsN/A$0.00+100.0%N/A-98.3%$20,000.00$70,000.000.0010Analyst ForecastHigh Trading VolumeVAXXVaxxinityN/A$0.00-98.0%N/A-99.3%$13,000.00N/A0.0090AMPEAmpio PharmaceuticalsN/A$0.01flatN/A-99.9%$11,000.00N/A0.0020Analyst ForecastNews CoverageEVLOEvelo BiosciencesN/A$0.00flatN/A-95.3%$9,000.00N/A0.00120Options VolumeNews CoverageCMRAComera Life SciencesN/A$0.00flatN/A-99.4%$6,000.00$630,000.000.002High Trading VolumeGNCAGenocea BiosciencesN/AN/AN/AN/A$6,000.00$1.91M0.0070Analyst ForecastSTABStatera BiopharmaN/A$0.00flatN/A-83.3%$5,000.00N/A0.0020CALACalithera BiosciencesN/A$0.00flatN/A-97.0%$3,000.00N/A0.0060Analyst ForecastNews CoverageCLVRClever LeavesN/A$0.00+900.0%N/A-100.0%$2,000.00$17.42M0.00560Gap UpHigh Trading VolumeEFTReFFECTOR Therapeutics1.0633 of 5 stars$0.00flat$24.00+11,999,900.0%-100.0%$1,000.00$3.55M0.0010 Related Companies and Tools Related Companies Navidea Biopharmaceuticals Competitors Vaxxinity Competitors Ampio Pharmaceuticals Competitors Evelo Biosciences Competitors Comera Life Sciences Competitors Genocea Biosciences Competitors Statera Biopharma Competitors Calithera Biosciences Competitors Clever Leaves Competitors eFFECTOR Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SCPS) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scopus BioPharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Scopus BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
